Atlas Trials

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

RecordFirmDate
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (NCT06038539)Biocon Biologics UK Ltd2025-01-06

Track HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients automatically

Every clearance here is in the API, with alerts when new ones post.